Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, Thomas D; MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: ran- domised controlled trial. Lancet. 2004;363:1491 1502. 515. Hobson RW 2nd, Weiss DG, Fields WS, Goldstone J, Moore WS, Towne JB, Wright CB. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis: the Veterans Affairs Cooperative Study Group. N Engl J Med. 1993;328:221 227. 516. Hass WK, Fields WS, North RR, Kircheff II, Chase NE, Bauer RB. Joint Study of Extracranial Arterial Occlusion, II: arteriography, techniques, sites, and complications. JAMA. 1968;203:961 968. 517. Moore WS, Young B, Baker WH, Robertson JT, Toole JF, Vescera CL, Howard VJ. Surgical results: a justification of the surgeon selection process for the ACAS trial: the ACAS Investigators. J Vasc Surg. 1996;23:323 328. 518. Thiex R, Norbash AM, Frerichs KU. The safety of dedicated-team cath- eter-based diagnostic cerebral angiography in the era of advanced nonin- vasive imaging. AJNR Am J Neuroradiol. 2010;31:230 234. 519. Kaufmann TJ, Huston J 3rd, Mandrekar JN, Schleck CD, Thielen KR, Kallmes DF. Complications of diagnostic cerebral angiography: evalua- tion of 19,826 consecutive patients. Radiology. 2007;243:812 819. 520. Howard G, Chambless LE, Baker WH, Ricotta JJ, Jones AM, O Leary D, Howard VJ, Elliott TJ, Lefkowitz DS, Toole JF. A multicenter validation study of Doppler ultrasound versus angiography. J Stroke Cerebrovasc Dis. 1991;1:166 173. 521. Johnston DC, Goldstein LB. Clinical carotid endarterectomy decision making: noninvasive vascular imaging versus angiography. Neurology. 2001;56:1009 1015. 522. Koelemay MJ, Nederkoorn PJ, Reitsma JB, Majoie CB. Systematic review of computed tomographic angiography for assessment of carotid artery disease. Stroke. 2004;35:2306 2312. 523. Fine-Edelstein JS, Wolf PA, O Leary DH, Poehlman H, Belanger AJ, Kase CS, D Agostino RB.


Fine-Edelstein JS, Wolf PA, O Leary DH, Poehlman H, Belanger AJ, Kase CS, D Agostino RB. Precursors of extracranial carotid atheroscle- rosis in the Framingham study. Neurology. 1994;44:1046 1050. 524. Weber F. Risk factors for subclinical carotid atherosclerosis in healthy men. Neurology. 2002;59:524 528. 525. Ratchford EV, Jin Z, Di Tullio MR, Salameh MJ, Homma S, Gan R, Boden-Albala B, Sacco RL, Rundek T. Carotid bruit for detection of hemodynamically significant carotid stenosis: the Northern Manhattan Study. Neurol Res. 2009;31:748 752. 526. Rubin MN, Barrett KM, Brott TG, Meschia JF. Asymptomatic carotid stenosis: What we can learn from the next generation of random- ized clinical trials. J R Soc Med Cardiovasc Dis. http://cvd.sagepub. com/content/3/2048004014529419. doi: 10.117/2048004014529419. Accessed May 1, 2014. 527. McPhee JT, Hill JS, Ciocca RG, Messina LM, Eslami MH. Carotid endarterectomy was performed with lower stroke and death rates than carotid artery stenting in the United States in 2003 and 2004. J Vasc Surg. 2007;46:1112 1118. 528. Kresowik TF, Bratzler DW, Kresowik RA, Hendel ME, Grund SL, Brown KR, Nilasena DS. Multistate improvement in process and out- comes of carotid endarterectomy. J Vasc Surg. 2004;39:372 380. 529. Voeks JH, Howard G, Roubin GS, Malas MB, Cohen DJ, Sternbergh WC 3rd, Aronow HD, Eskandari MK, Sheffet AJ, Lal BK, Meschia JF, Brott TG; CREST Investigators. Age and outcomes after carotid stenting and endarterectomy: the Carotid Revascularization Endarterectomy Versus Stenting Trial. Stroke. 2011;42:3484 3490. 530. White RA, Sicard GA, Zwolak RM, Sidawy AN, Schermerhorn ML, Shackelton RJ, Siami FS. Society of Vascular Surgery Vascular Registry comparison of carotid artery stenting outcomes for atherosclerotic vs non- atherosclerotic carotid artery disease. J Vasc Surg. 2010;51:1116 1123. 531. Goodney PP, Lucas FL, Likosky DS, Malenka DJ, Fisher ES. Changes in the use of carotid revascularization among the Medicare population. Arch Surg. 2008;143:170 173.


Changes in the use of carotid revascularization among the Medicare population. Arch Surg. 2008;143:170 173. 532. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, Whitlow P, Strickman NE, Jaff MR, Popma JJ, Snead DB, Cutlip DE, Firth BG, Ouriel K; Stenting andAngioplasty With Protection in Patients at High Risk for Endarterectomy Investigators. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004;351:1493 1501. 533. Gurm HS, Yadav JS, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, Ansel G, Strickman NE, Wang H, Cohen SA, Massaro JM, Cutlip DE, SAPPHIRE Investigators. Long-term results of carotid stenting versus endarterectomy in high-risk patients. 2008;358:1572 1579. 534. Goldstein LB. New data about stenting versus endarterectomy for symp- tomatic carotid artery stenosis. Curr Treat Options Cardiovasc Med. 2009;11:232 240. 535. Brott TG, Hobson RW 2nd, Howard G, Roubin GS, Clark WM, Brooks W, Mackey A, Hill MD, Leimgruber PP, Sheffet AJ, Howard VJ, Moore WS, Voeks JH, Hopkins LN, Cutlip DE, Cohen DJ, Popma JJ, Ferguson RD, Cohen SN, Blackshear JL, Silver FL, Mohr JP, Lal BK, Meschia JF; CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363:11 23. 536. Pawaskar M, Satiani B, Balkrishnan R, Starr JE. Economic evaluation of carotid artery stenting versus carotid endarterectomy for the treatment of carotid artery stenosis. J Am Coll Surg. 2007;205:413 419. 537. McPhee JT, Schanzer A, Messina LM, Eslami MH. Carotid artery stent- ing has increased rates of postprocedure stroke, death, and resource utilization than does carotid endarterectomy in the United States, 2005. J Vasc Surg. 2008;48:1442 1450, 1450.e1. 538. Young KC, Holloway RG, Burgin WS, Benesch CG. A cost-effective- ness analysis of carotid artery stenting compared with endarterectomy. J Stroke Cerebrovasc Dis. 2010;19:404 409. 539.


A cost-effective- ness analysis of carotid artery stenting compared with endarterectomy. J Stroke Cerebrovasc Dis. 2010;19:404 409. 539. Lal BK, Meschia JF, Brott TG. CREST-2: Guiding treatments for asymp- tomatic carotid disease. Endovascular Today. September 2013:73 76. 540. US Preventive Services Task Force. Screening for carotid artery stenosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007;147:854 859. 541. Abbott AL. Medical (nonsurgical) intervention alone is now best for pre- vention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke. 2009;40:e573-e583. 542. Marquardt L, Geraghty OC, Mehta Z, Rothwell PM. Low risk of ipsi- lateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. Stroke. 2010;41:e11-e17. 543. Woo K, Garg J, Hye RJ, Dilley RB. Contemporary results of carotid end- arterectomy for asymptomatic carotid stenosis. Stroke. 2010;41:975 979. 544. Halliday A, Harrison M, Hayter E, Kong X, Mansfield A, Marro J, Pan H, Peto R, Potter J, Rahimi K, Rau A, Robertson S, Streifler J, Thomas D; Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. 10-Year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet. 2010;376:1074 1084. 545. Rothwell PM, Goldstein LB. Carotid endarterectomy for asymp- tomatic carotid stenosis: asymptomatic carotid surgery trial. Stroke. 2004;35:2425 2427. 546. Hirt LS. Progression rate and ipsilateral neurological events in asymp- tomatic carotid stenosis. Stroke. 2014;45:702 706. 547. Adams RJ. Neurologic complications. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principals and Clinical Practice. New York, NY: Raven Press; 1994;599 621. 548.


Sickle Cell Disease: Basic Principals and Clinical Practice. New York, NY: Raven Press; 1994;599 621. 548. Armstrong FD, Thompson RJ Jr, Wang W, Zimmerman R, Pegelow CH, Miller S, Moser F, Bello J, Hurtig A, Vass K. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease: Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Pediatrics. 1996;97(pt 1):864 870. 549. Ohene-Frempong K,Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288 294. 550. Adams R, McKie V, Nichols F, Carl E, Zhang DL, McKie K, Figueroa R, Litaker M, ThompsonW, Hess D. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992;326:605 610. 551. Adams RJ, McKie VC, Carl EM, Nichols FT, Perry R, Brock K, McKie K, Figueroa R, Litaker M, Weiner S, Brambilla D. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol. 1997;42:699 704. 552. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5 11. 553. Kwiatkowski JL, Granger S, Brambilla DJ, Brown RC, Miller ST, Adams RJ; STOP Trial Investigators. Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease: extended analysis from the STOP trial. Br J Haematol. 2006;134:333 339. 554. Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke rates in Californian children with sickle cell disease. Blood. 2004;104:336 339. 555. Ovbiagele B, Adams RJ.


Declining stroke rates in Californian children with sickle cell disease. Blood. 2004;104:336 339. 555. Ovbiagele B, Adams RJ. Trends in comorbid sickle cell disease among stroke patients. J Neurol Sci. 2012;313:86 91. 556. Jones A, Granger S, Brambilla D, Gallagher D, Vichinsky E, Woods G, Berman B, Roach S, Nichols F, Adams RJ. Can peak systolic velocities be used for prediction of stroke in sickle cell anemia? Pediatr Radiol. 2005;35:66 72. 557. McCarville MB, Goodin GS, Fortner G, Li CS, Smeltzer MP, Adams R, Wang W. Evaluation of a comprehensive transcranial Doppler screen- ing program for children with sickle cell anemia. Pediatr Blood Cancer. 2008;50:818 821. 558. Raphael JL, Shetty PB, Liu H, Mahoney DH, Mueller BU. A critical assessment of transcranial Doppler screening rates in a large pediatric sickle cell center: opportunities to improve healthcare quality. Pediatr Blood Cancer. 2008;51:647 651. 559. Eckrich MJ, Wang WC, Yang E, Arbogast PG, Morrow A, Dudley JA, Ray WA, Cooper WO. Adherence to transcranial Doppler screening guidelines among children with sickle cell disease. Pediatr Blood Cancer. 2013;60:270 274. 560. National Institutes of Health. Management of Sickle Cell Disease. Bethesda, MD: National Institutes of Health; 2002. Publication No. 02-2117. 561. Section on Hematology/Oncology Committee on Genetics; American Academy of Pediatrics. Health supervision for children with sickle cell disease. Pediatrics. 2002;109:526 535. 562. Sampaio Silva G, Vicari P, Figueiredo MS, Filho AC, Valadi N, Massaro AR. Transcranial Doppler in adult patients with sickle cell disease. Cerebrovasc Dis. 2006;21:38 41. 563. Valadi N, Silva GS, Bowman LS, Ramsingh D, Vicari P, Filho AC, Massaro AR, Kutlar A, Nichols FT, Adams RJ. Transcranial Doppler ultrasonography in adults with sickle cell disease. Neurology. 2006;67:572 574. 564. Kirkham FJ, Hewes DK, Prengler M, Wade A, Lane R, Evans JP. Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. Lancet.


Kirkham FJ, Hewes DK, Prengler M, Wade A, Lane R, Evans JP. Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. Lancet. 2001;357:1656 1659. 565. Hollocks MJ, Kok TB, Kirkham FJ, Gavlak J, Inusa BP, DeBaun MR, de Haan M. Nocturnal oxygen desaturation and disordered sleep as a potential factor in executive dysfunction in sickle cell anemia. J Int Neuropsychol Soc. 2012;18:168 173. 566. Miller ST, Macklin EA, Pegelow CH, Kinney TR, Sleeper LA, Bello JA, DeWitt LD, Gallagher DM, Guarini L, Moser FG, Ohene-Frempong K, Sanchez N, Vichinsky EP, Wang WC, Wethers DL, Younkin DP, Zimmerman RA, DeBaun MR; Cooperative Study of Sickle Cell Disease. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 2001;139:385 390. 567. DeBaun MR, Gordon M, McKinstry RC, Noetzel DA, White SA, Sarnaik ER, Meier TH, Howard S, Majumdar S, Inusa BPD, Telfer PT, Kirby- Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371:699 671. 568. Telfer PT, Evanson J, Butler P, Hemmaway C, Abdulla C, Gadong N, Whitmarsh S, Kaya B, Kirkham FJ. Cervical carotid artery dis- ease in sickle cell anemia: clinical and radiological features. Blood. 2011;118:6192 6199. 569. Bernaudin F, Verlhac S, Coic L, Lesprit E, Brugieres P, Reinert P. Long- term follow-up of pediatric sickle cell disease patients with abnormal high velocities on transcranial Doppler. Pediatr Radiol. 2005;35:242 248. 570.


Bernaudin F, Verlhac S, Coic L, Lesprit E, Brugieres P, Reinert P. Long- term follow-up of pediatric sickle cell disease patients with abnormal high velocities on transcranial Doppler. Pediatr Radiol. 2005;35:242 248. 570. Hsu LL, Miller ST, Wright E, Kutlar A, McKie V, Wang W, Pegelow CH, Driscoll C, Hurlet A, Woods G, Elsas L, Embury S, Adams RJ; Stroke Prevention Trial (STOP) and the Cooperative Study of Sickle Cell Disease (CSSCD). Alpha thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. J Pediatr Hematol Oncol. 2003;25:622 628. 571. Bernaudin F,Verlhac S, Chevret S, Torres M, Coic L,Arnaud C, Kamdem A, Hau I, Grazia Neonato M, Delacourt C. G6PD deficiency, absence of alpha-thalassemia, and hemolytic rate at baseline are significant indepen- dent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood. 2008;112:4314 4317. 572. Rees DC, Dick MC, Height SE, O Driscoll S, Pohl KR, Goss DE, Deane CR. A simple index using age, hemoglobin, and aspartate transaminase predicts increased intracerebral blood velocity as measured by transcra- nial Doppler scanning in children with sickle cell anemia. Pediatrics. 2008;121:e1628-e1632. 573. Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Chevret S, Hau I, Coic L, Leveille E, Lemarchand E, Lesprit E, Abadie I, Medejel N, Madhi F, Lemerle S, Biscardi S, Bardakdjian J, Galacteros F, Torres M, Kuentz M, Ferry C, Socie G, Reinert P, Delacourt C. Impact of early transcra- nial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood. 2011;117:1130 1140; quiz 1436. 574. Silva CM, Giovani P, Viana MB. High reticulocyte count is an indepen- dent risk factor for cerebrovascular disease in children with sickle cell anemia. Pediatr Blood Cancer. 2011;56:116 121. 575.


High reticulocyte count is an indepen- dent risk factor for cerebrovascular disease in children with sickle cell anemia. Pediatr Blood Cancer. 2011;56:116 121. 575. Savage WJ, Barron-Casella E, Fu Z, Dulloor P, Williams L, Crain BJ, White DA, Jennings JM, Van Eyk JE, Debaun MR, Everett A, Casella JF. Plasma glial fibrillary acidic protein levels in children with sickle cell disease. Am J Hematol. 2011;86:427 429. Meschia et al Guidelines for the Primary Prevention of Stroke 3823 576. Asare K, Gee BE, Stiles JK, Wilson NO, Driss A, Quarshie A, Adams RJ, Kutlar A, Hibbert JM. Plasma interleukin-1beta concentration is associ- ated with stroke in sickle cell disease. Cytokine. 2010;49:39 44. 577. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet. 2005;37:435 440. 578. Hoppe C, Klitz W, D Harlingue K, Cheng S, Grow M, Steiner L, Noble J, Adams R, Styles L; Stroke Prevention Trial in Sickle Cell Anemia (STOP) Investigators. Confirmation of an association between the TNF(- 308) promoter polymorphism and stroke risk in children with sickle cell anemia. Stroke. 2007;38:2241 2246. 579. Flanagan JM, Frohlich DM, Howard TA, Schultz WH, Driscoll C, Nagasubramanian R, Mortier NA, Kimble AC, Aygun B, Adams RJ, Helms RW, Ware RE. Genetic predictors for stroke in children with sickle cell anemia. Blood. 2011;117:6681 6684. 580. Thangarajh M, Yang G, Fuchs D, Ponisio MR, McKinstry RC, Jaju A, Noetzel MJ, Casella JF, Barron-Casella E, Hooper WC, Boulet SL, Bean CJ, Pyle ME, Payne AB, Driggers J, Trau HA, Vendt BA, Rodeghier M, DeBaun MR. Magnetic resonance angiography-defined intracranial vas- culopathy is associated with silent cerebral infarcts and glucose-6-phos- phate dehydrogenase mutation in children with sickle cell anaemia. Br J Haematol. 2012;159:352 359. 581.


Magnetic resonance angiography-defined intracranial vas- culopathy is associated with silent cerebral infarcts and glucose-6-phos- phate dehydrogenase mutation in children with sickle cell anaemia. Br J Haematol. 2012;159:352 359. 581. Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood. 1993;81:1109 1123. 582. Vichinsky E, Luban N, Wright E, Olivieri N, Driscoll C, Pegelow C, Files B, Adams RJ. Prospective cell phenotype matching in STOP - a multi- center transfusion trial. Paper presented at: 23rd Annual Meeting of the National Sickle Cell Disease Program; March 1999; San Francisco, CA. 583. National Heart, Lung, and Blood Institute. Clinical Alert: NHLBI Stops Study Testing How Long Children with Sickle Cell Anemia Should Have Blood Transfusions to Prevent Stroke. December 5, 2004. http://www. long-children-with-sickle-cell-anemia-should-have-blood-transfusions- to-prevent-stroke.html. Accessed March 19, 2013. 584. Adams RJ, Brambilla D; Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophy- lactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769 2778. 585. Abboud MR, Yim E, Musallam KM, Adams RJ; STOP II Study Investigators. Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood. 2011;118:894 898. F, Corazza F, Devalck C, Dresse MF, Hunninck K, Klein A, Le PQ, Loop M, Maes P, Philippet P, Sariban E, Van Geet C, Ferster A. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood. 2005;105:2685 2690. 587. Kratovil T, Bulas D, Driscoll MC, Speller-Brown B, McCarter R, Minniti CP. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatr Blood Cancer. 2006;47:894 900. 588. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler flow velocities in chil- dren with sickle cell anemia. Blood.


Hydroxyurea therapy lowers transcranial Doppler flow velocities in chil- dren with sickle cell anemia. Blood. 2007;110:1043 1047. 589. Lebensburger JD, Miller ST, Howard TH, Casella JF, Brown RC, Lu M, Iyer RV, Sarnaik S, Rogers ZR, Wang WC; BABY HUG Investigators. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatr Blood Cancer. 2012;59:675 678. 590. Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y, Vannier JP, Yakouben K, Thuret I, Bordigoni P, Fischer A, Lutz P, Stephan JL, Dhedin N, Plouvier E, Margueritte G, Bories D, Verlhac S, Esperou H, Coic L, Vernant JP, Gluckman E; SFGM-TC. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110:2749 2756. 591. Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F, Buchanan GR, Bunin N, Dickerhoff R, Giller R, Haut PR, Horan J, Hsu LL, Kamani N, Levine JE, Margolis D, Ohene- Frempong K, Patience M, Redding-Lallinger R, Roberts IA, Rogers ZR, Sanders JE, Scott JP, Sullivan KM; Multicenter Study of Bone Marrow Transplantation for Sickle Cell Disease. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010;16:263 272. 592. Tzourio C, Tehindrazanarivelo A, Iglesias S, Alperovitch A, Chedru F, d Anglejan-Chatillon J, Bousser M-G. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ. 1995;310:830 833. 593. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med. 2010;123:612 624. 594. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914. 595. Etminan M, Takkouche B, Isorna FC, Samii A.


2009;339:b3914. 595. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of obser- vational studies. BMJ. 2005;330:63. 596. Kurth T, Schurks M, Logroscino G, Buring JE. Migraine frequency and risk of cardiovascular disease in women. Neurology. 2009;73:581 588. 597. Schurks M, Buring JE, Kurth T. Migraine, migraine features, and cardio- vascular disease. Headache. 2010;50:1031 1040. 598. Kurth T, Kase CS, Schurks M, Tzourio C, Buring JE. Migraine and risk of haemorrhagic stroke in women: prospective cohort study. BMJ. 2010;341:c3659. 599. Scher AI, Gudmundsson LS, Sigurdsson S, Ghambaryan A, Aspelund T, Eiriksdottir G, van Buchem MA, Gudnason V, Launer LJ. Migraine headache in middle age and late-life brain infarcts. JAMA. 2009;301:2563 2570. 600. Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Infarcts in the posterior circulation territory in migraine: the population-based MRI CAMERA study. Brain. 2005;128:2068 2077. 601. Kruit MC, van Buchem MA, Launer LJ, Terwindt GM, Ferrari MD. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accu- mulation: the population-based MRI CAMERA study. Cephalalgia. 2010;30:129 136. 602. Cavestro C, Richetta L, L Episcopo MR, Pedemonte E, Duca S, Di Pietrantonj C. Anatomical variants of the circle of Willis and brain lesions in migraineurs. Can J Neurol Sci. 2011;38:494 499. 603. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365 391. 604. Martinez-Sanchez P, Martinez-Martinez M, Fuentes B, Cuesta MV, Cuellar-Gamboa L, Idrovo-Freire L, Fernandez-Dominguez J, Diez- Tejedor E. Migraine and hypercoagulable states in ischemic stroke. Cephalalgia. 2011;31:1609 1617. 605. MacClellan L, Giles WH, Cole JW, Wozniak MA, Stern BJ, Mitchell B, Kittner SJ. Probable migraine with visual aura and risk of ischemic stroke: the Stroke Prevention inYoungWomen Study. Stroke. 2007;38:2438 2445. 606.


Probable migraine with visual aura and risk of ischemic stroke: the Stroke Prevention inYoungWomen Study. Stroke. 2007;38:2438 2445. 606. Schurks M, Zee RY, Buring JE, Kurth T. ACE D/I polymor- phism, migraine, and cardiovascular disease in women. Neurology. 2009;72:650 656. 607. Webster M, Chancellor A, Smith H, Swift D, Sharpe D, Bass N, Glasgow G. Patent foramen ovale in young stroke patients. Lancet. 1988;2:11 12. 608. Anzola G, Magoni M, Guindani M, Rozzini L, Dalla Volta G. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology. 1999;52:1622 1626. 609. Olesen J, Friberg L, Olsen T, Andersen A, Lassen N, Hansen P, Karle A. Ischaemia-induced (symptomatic) migraine attacks may be more frequent than migraine-induced ischaemic insults. Brain. 1993;116(pt 1):187 202. 610. Dowson A, Mullen M, Peatfield R, Muir K, Khan A, Wells C, Lipscombe S, Rees T, De Giovanni J, Morrison W, Hildick-Smith D, Elrington G, Hillis W, Malik I, Rickards A. Migraine Intervention With STARFlex Technology (MIST) Trial: a prospective, multicenter, double-blinded, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation. 2008;117:1397 1404. 611. Tobis J. Management of patients with refractory migraine and PFO: is MIST I relevant? Catheter Cardiovasc Interv. 2008;72:60 64. 612. Rundek T, Elkind MS, Di Tullio MR, Carrera E, Jin Z, Sacco RL, Homma S. Patent foramen ovale and migraine: a cross-sectional study from the Northern Manhattan Study (NOMAS). Circulation. 2008;118:1419 1424. 613. Garg P, Servoss SJ, Wu JC, Bajwa ZH, Selim MH, Dineen A, Kuntz RE, Cook EF, Mauri L. Lack of association between migraine headache and patent foramen ovale: results of a case-control study. Circulation. 2010;121:1406 1412. 614.


Garg P, Servoss SJ, Wu JC, Bajwa ZH, Selim MH, Dineen A, Kuntz RE, Cook EF, Mauri L. Lack of association between migraine headache and patent foramen ovale: results of a case-control study. Circulation. 2010;121:1406 1412. 614. Davis D, Gregson J, Willeit P, Stephan B, Al-Shahi Salman R, Brayne C. Patent foramen ovale, ischemic stroke and migraine: systematic review and stratified meta-analysis of association studies. Neuroepidemiology. 2013;40:56 67. 615. Kurth T, Diener HC, Buring JE. Migraine and cardiovascular disease in women and the role of aspirin: subgroup analyses in the Women s Health Study. Cephalalgia. 2011;31:1106 1115. 616. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486 2497. 617. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, HongY, Eckel RH. Clinical implications of obesity with specific focus on cardio- vascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2004;110:2952 2967. 618. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366:1059 1062. 619. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity.


Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syn- drome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640 1645. 620. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709 2716. 621. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415 1428. 622. Jiamsripong P, Mookadam M, Alharthi MS, Khandheria BK, Mookadam F. The metabolic syndrome and cardiovascular disease: part 2. Prev Cardiol. 2008;11:223 229. 623. MokdadAH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195 1200. 624. Eckel RH. Clinical practice: nonsurgical management of obesity in adults. N Engl J Med. 2008;358:1941 1950. 625. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all- cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71 82. 626. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocr Rev. 2008;29:777 822. 627. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes. 2010;2:180 193. 628.


Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes. 2010;2:180 193. 628. Bonora E, Willeit J, Kiechl S, Oberhollenzer F, Egger G, Bonadonna R, Muggeo M. Relationship between insulin and carotid athero- sclerosis in the general population: the Bruneck Study. Stroke. 1997;28:1147 1152. 629. Haffner SM, D Agostino R, Mykkanen L, Hales CN, Savage PJ, Bergman RN, O Leary D, Rewers M, Selby J, Tracy R, Saad MF. Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study. Stroke. 1998;29:1498 1503. 630. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke. 1994;25:1157 1164. 631. Kaarisalo MM, Raiha I, Arve S, Lehtonen A. Impaired glucose tolerance as a risk factor for stroke in a cohort of non-institutionalised people aged 70 years. Age Ageing. 2006;35:592 596. 632. Lindahl B, Dinesen B, Eliasson M, Roder M, Hallmans G, Stegmayr B. High proinsulin levels precede first-ever stroke in a nondiabetic popula- tion. Stroke. 2000;31:2936 2941. 633. Oizumi T, Daimon M, JimbuY, Wada K, Kameda W, Susa S,Yamaguchi H, Ohnuma H, Tominaga M, Kato T. Impaired glucose tolerance is a risk factor for stroke in a Japanese sample: the Funagata study. Metabolism. 2008;57:333 338. 634. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Stroke. 1998;29:1860 1866. 635. QureshiAI, Giles WH, Croft JB. Impaired glucose tolerance and the like- lihood of nonfatal stroke and myocardial infarction: the Third National Health and Nutrition Examination Survey. Stroke. 1998;29:1329 1332. 636.


Impaired glucose tolerance and the like- lihood of nonfatal stroke and myocardial infarction: the Third National Health and Nutrition Examination Survey. Stroke. 1998;29:1329 1332. 636. Vermeer SE, Sandee W, Algra A, Koudstaal PJ, Kappelle LJ, Dippel DW; Dutch TIA Trial Study Group. Impaired glucose tolerance increases stroke risk in nondiabetic patients with transient ischemic attack or minor ischemic stroke. Stroke. 2006;37:1413 1417. 637. Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso M, Kuusisto J. The metabolic syndrome predicts incident stroke: a 14-year follow-up study in elderly people in Finland. Stroke. 2008;39:1078 1083. 638. Wannamethee SG, Perry IJ, Shaper AG. Nonfasting serum glucose and insulin concentrations and the risk of stroke. Stroke. 1999;30:1780 1786. 639. Urabe T, Watada H, Okuma Y, Tanaka R, Ueno Y, Miyamoto N, Tanaka Y, Hattori N, Kawamori R. Prevalence of abnormal glucose metabolism and insulin resistance among subtypes of ischemic stroke in Japanese patients. Stroke. 2009;40:1289 1295. 640. Anand SS, Dagenais GR, Mohan V, Diaz R, Probstfield J, Freeman R, Shaw J, Lanas F, Avezum A, Budaj A, Jung H, Desai D, Bosch J, Yusuf S, Gerstein HC; EpiDREAM Investigators. Glucose levels are associ- ated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Prev Cardiol. 2012;19:755 764. 641. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syn- drome. Lancet. 2010;375:181 183. 642. Hanchaiphiboolkul S, Suwanwela NC, Poungvarin N, Nidhinandana S, Puthkhao P, Towanabut S, Tantirittisak T, Suwantamee J, Samsen M. Risk of metabolic syndrome for stroke is not greater than the sum of its components: Thai Epidemiologic Stroke (TES) Study. J Stroke Cerebrovasc Dis. 2013;22:e264 e270. 643. Ninomiya JK, L Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS.


Ninomiya JK, L Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarc- tion and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004;109:42 46. 644. Milionis HJ, Rizos E, Goudevenos J, Seferiadis K, Mikhailidis DP, Elisaf MS. Components of the metabolic syndrome and risk for first- ever acute ischemic nonembolic stroke in elderly subjects. Stroke. 2005;36:1372 1376. 645. Park YK, Yi HJ, Lee YJ, Cho H, Chun HJ, Oh SJ. The relationship between metabolic syndrome (MetS) and spontaneous intracerebral hemorrhage (ICH). Neurol Sci. 2013;34:1523 1528. 646. Novo S, Peritore A, Guarneri FP, Corrado E, Macaione F, Evola S, Novo G. Metabolic syndrome (MetS) predicts cardio and cerebrovascular events in a twenty years follow-up: a prospective study. Atherosclerosis. 2012;223:468 472. 647. Chen HJ, Bai CH, Yeh WT, Chiu HC, Pan WH. Influence of metabolic syndrome and general obesity on the risk of ischemic stroke. Stroke. 2006;37:1060 1064. 648. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospec- tive cohort study in patients with atherosclerotic cardiovascular disease. Stroke. 2005;36:1366 1371. 649. Kurl S, Laukkanen JA, Niskanen L, Laaksonen D, Sivenius J, Nyyssonen K, Salonen JT. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke. 2006;37:806 811. 650. Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D Agostino RB, Wolf PA. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med. 2006;166:106 111. 651. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovas- cular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113 1132. 652.


The metabolic syndrome and cardiovas- cular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113 1132. 652. Okamura T, Kokubo Y, Watanabe M, Higashiyama A, Ono Y, Nishimura K, Okayama A, Miyamoto Y. A revised definition of the metabolic syndrome predicts coronary artery disease and ischemic stroke after adjusting for low density lipoprotein cholesterol in a 13-year cohort study of Japanese: the Suita study. Atherosclerosis. 2011;217:201 206. 653. Yun JE, Won S, Sung J, Jee SH. Impact of metabolic syndrome indepen- dent of insulin resistance on the development of cardiovascular disease. Circ J. 2012;76:2443 2448. 654. Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, Altafullah I, Ledbetter LY, MacLeod MJ, Scott R, Hennerici M, Zivin JA, Welch KM; SPARCL Investigators. Risk of stroke and car- diovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol. 2011;68:1245 1251. Meschia et al Guidelines for the Primary Prevention of Stroke 3825 655. Khang YH, Cho SI, Kim HR. Risks for cardiovascular disease, stroke, ischaemic heart disease, and diabetes mellitus associated with the meta- bolic syndrome using the new harmonised definition: findings from nationally representative longitudinal data from an Asian population. Atherosclerosis. 2010;213:579 585. 656. Cortez-Dias N, Martins S, Belo A, Fiuza M; Investigadores do estudo VALSIM. Comparison of definitions of metabolic syndrome in rela- tion to risk for coronary artery disease and stroke. Rev Port Cardiol. 2011;30:139 169. 657. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.


Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195 2207. 658. Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Effects of high-dose atorv- astatin on cerebrovascular events in patients with stable coronary dis- ease in the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2006;48:1793 1799. 659. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators. Reduction of low-density lipoprotein cho- lesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919 928. 660. National Institute on Alcohol Abuse and Alcoholism Web site. http:// www.niaaa.nih.gov. Accessed December 23, 2013. 661. Gill JS, Zezulka AV, Shipley MJ, Gill SK, Beevers DG. Stroke and alco- hol consumption. N Engl J Med. 1986;315:1041 1046. 662. Hillbom M, Numminen H, Juvela S. Recent heavy drinking of alcohol and embolic stroke. Stroke. 1999;30:2307 2312. 663. Klatsky AL, Armstrong MA, Friedman GD, Sidney S. Alcohol drink- ing and risk of hospitalization for ischemic stroke. Am J Cardiol. 2001;88:703 706. 664. Mazzaglia G, Britton AR, Altmann DR, Chenet L. Exploring the rela- tionship between alcohol consumption and non-fatal or fatal stroke: a systematic review. Addiction. 2001;96:1743 1756. 665. Wannamethee SG, Shaper AG. Patterns of alcohol intake and risk of stroke in middle-aged British men. Stroke. 1996;27:1033 1039. 666. Berger K, Ajani UA, Kase CS, Gaziano JM, Buring JE, Glynn RJ, Hennekens CH.


Berger K, Ajani UA, Kase CS, Gaziano JM, Buring JE, Glynn RJ, Hennekens CH. Light-to-moderate alcohol consumption and risk of stroke among U.S. male physicians. N Engl J Med. 1999;341:1557 1564. 667. Chiuve SE, Rexrode KM, Spiegelman D, Logroscino G, Manson JE, Rimm EB. Primary prevention of stroke by healthy lifestyle. Circulation. 2008;118:947 954. 668. Djousse L, Levy D, Benjamin EJ, Blease SJ, Russ A, Larson MG, Massaro JM, D Agostino RB, Wolf PA, Ellison RC. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham study. Am J Cardiol. 2004;93:710 713. 669. Elkind MS, Sciacca R, Boden-Albala B, Rundek T, Paik MC, Sacco RL. Moderate alcohol consumption reduces risk of ischemic stroke: the Northern Manhattan Study. Stroke. 2006;37:13 19. 670. Gorelick PB, Rodin MB, Langenberg P, Hier DB, Costigan J. Weekly alcohol consumption, cigarette smoking, and the risk of ischemic stroke: results of a case-control study at three urban medical centers in Chicago, Illinois. Neurology. 1989;39:339 343. 671. Iso H, Baba S, Mannami T, Sasaki S, Okada K, Konishi M, Tsugane S; JPHC Study Group. Alcohol consumption and risk of stroke among mid- dle-aged men: the JPHC Study Cohort I. Stroke. 2004;35:1124 1129. 672. Malarcher AM, Giles WH, Croft JB, Wozniak MA, Wityk RJ, Stolley PD, Stern BJ, Sloan MA, Sherwin R, Price TR, Macko RF, Johnson CJ, Earley CJ, Buchholz DW, Kittner SJ. Alcohol intake, type of bev- erage, and the risk of cerebral infarction in young women. Stroke. 2001;32:77 83. 673. Sacco RL, Elkind M, Boden-Albala B, Lin IF, Kargman DE, Hauser WA, Shea S, Paik MC. The protective effect of moderate alcohol consumption on ischemic stroke. JAMA. 1999;281:53 60. 674. Stampfer MJ, Colditz GA, Willett WC, Speizer FE, Hennekens CH.


Stampfer MJ, Colditz GA, Willett WC, Speizer FE, Hennekens CH. A prospective study of moderate alcohol consumption and the risk of coro- nary disease and stroke in women. N Engl J Med. 1988;319:267 273. 675. Jimenez M, Chiuve SE, Glynn RJ, Stampfer MJ, Camargo CA Jr, Willett WC, Manson JE, Rexrode KM. Alcohol consumption and risk of stroke in women. Stroke. 2012;43:939 945. 676. Bos S, Grobbee DE, Boer JM, Verschuren WM, Beulens JW. Alcohol consumption and risk of cardiovascular disease among hypertensive women. Eur J Cardiovasc Prev Rehabil. 2010;17:119 126. 677. Klatsky AL, Armstrong MA, Friedman GD, Sidney S. Alcohol drinking and risk of hemorrhagic stroke. Neuroepidemiology. 2002;21:115 122. 678. Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J.Alcohol con- sumption and risk of stroke: a meta-analysis. JAMA. 2003;289:579 588. 679. Casolla B, Dequatre-Ponchelle N, Rossi C, Henon H, Leys D, Cordonnier C. Heavy alcohol intake and intracerebral hemorrhage: characteristics and effect on outcome. Neurology. 2012;79:1109 1115. 680. Mukamal KJ, Jensen MK, Gronbaek M, Stampfer MJ, Manson JE, Pischon T, Rimm EB. Drinking frequency, mediating biomarkers, and risk of myocardial infarction in women and men. Circulation. 2005;112:1406 1413. 681. Volcik KA, Ballantyne CM, Fuchs FD, Sharrett AR, Boerwinkle E. Relationship of alcohol consumption and type of alcoholic beverage con- sumed with plasma lipid levels: differences between Whites and African Americans of the ARIC study. Ann Epidemiol. 2008;18:101 107. 682. Miceli M, Alberti L, Bennardini F, Di Simplicio P, Seghieri G, Rao GH, Franconi F. Effect of low doses of ethanol on platelet function in long-life abstainers and moderate-wine drinkers. Life Sci. 2003;73:1557 1566. 683. Mukamal KJ, Massaro JM, Ault KA, Mittleman MA, Sutherland PA, Lipinska I, Levy D, D Agostino RB, Tofler GH.


Mukamal KJ, Massaro JM, Ault KA, Mittleman MA, Sutherland PA, Lipinska I, Levy D, D Agostino RB, Tofler GH. Alcohol con- sumption and platelet activation and aggregation among women and men: the Framingham Offspring Study. Alcohol Clin Exp Res. 2005;29:1906 1912. 684. McKenzie CR, Abendschein DR, Eisenberg PR. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associ- ated factor Xa. Arterioscler Thromb Vasc Biol. 1996;16:1285 1291. 685. Greenfield JR, Samaras K, Hayward CS, Chisholm DJ, Campbell LV. Beneficial postprandial effect of a small amount of alcohol on diabetes and cardiovascular risk factors: modification by insulin resistance. J Clin Endocrinol Metab. 2005;90:661 672. 686. Joosten MM, Beulens JW, Kersten S, Hendriks HF. Moderate alcohol consumption increases insulin sensitivity and ADIPOQ expression in postmenopausal women: a randomised, crossover trial. Diabetologia. 2008;51:1375 1381. 687. Rantakomi SH, Laukkanen JA, Sivenius J, Kauhanen J, Kurl S. Alcohol consumption and the risk of stroke among hypertensive and overweight men. J Neurol. 2013;260:534 539. 688. Hillbom M, Saloheimo P, Juvela S. Alcohol consumption, blood pres- sure, and the risk of stroke. Curr Hypertens Rep. 2011;13:208 213. 689. Judd SE, McClure LA, Howard VJ, Lackland DT, Halanych JH, Kabagambe EK. Heavy drinking is associated with poor blood pressure control in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Int J Environ Res Public Health. 2011;8:1601 1612. 690. Wakabayashi I, Araki Y. Influences of gender and age on relationships between alcohol drinking and atherosclerotic risk factors. Alcohol Clin Exp Res. 2010;34(suppl 1):S54-S60. 691. Foerster M, Marques-Vidal P, Gmel G, Daeppen JB, Cornuz J, Hayoz D, Pecoud A, Mooser V, Waeber G, Vollenweider P, Paccaud F, Rodondi N. Alcohol drinking and cardiovascular risk in a population with high mean alcohol consumption. Am J Cardiol. 2009;103:361 368. 692.


Foerster M, Marques-Vidal P, Gmel G, Daeppen JB, Cornuz J, Hayoz D, Pecoud A, Mooser V, Waeber G, Vollenweider P, Paccaud F, Rodondi N. Alcohol drinking and cardiovascular risk in a population with high mean alcohol consumption. Am J Cardiol. 2009;103:361 368. 692. Ohira T, Tanigawa T, Tabata M, Imano H, Kitamura A, Kiyama M, Sato S, Okamura T, Cui R, Koike KA, Shimamoto T, Iso H. Effects of habitual alcohol intake on ambulatory blood pressure, heart rate, and its variabil- ity among Japanese men. Hypertension. 2009;53:13 19. 693. Taylor B, Irving HM, Baliunas D, Roerecke M, Patra J, Mohapatra S, Rehm J. Alcohol and hypertension: gender differences in dose-response relationships determined through systematic review and meta-analysis. Addiction. 2009;104:1981 1990. 694. Christie IC, Price J, Edwards L, Muldoon M, Meltzer CC, Jennings JR. Alcohol consumption and cerebral blood flow among older adults. Alcohol. 2008;42:269 275. 695. Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Gronbaek M. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation. 2005;112:1736 1742. 696. Liang Y, Mente A, Yusuf S, Gao P, Sleight P, Zhu J, Fagard R, Lonn E, Teo KK; ONTARGET and TRANSCEND Investigators. Alcohol con- sumption and the risk of incident atrial fibrillation among people with cardiovascular disease. CMAJ. 2012;184:E857 E866. 697. Kodama S, Saito K, Tanaka S, Horikawa C, Saito A, HeianzaY, Anasako Y, Nishigaki Y, Yachi Y, Iida KT, Ohashi Y, Yamada N, Sone H. Alcohol consumption and risk of atrial fibrillation: a meta-analysis. J Am Coll Cardiol. 2011;57:427 436. 698. Samokhvalov AV, Irving HM, Rehm J. Alcohol consumption as a risk factor for atrial fibrillation: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil. 2010;17:706 712. 699. Kurth T, Moore SC, Gaziano JM, Kase CS, Stampfer MJ, Berger K, Buring JE.


Kurth T, Moore SC, Gaziano JM, Kase CS, Stampfer MJ, Berger K, Buring JE. Healthy lifestyle and the risk of stroke in women. Arch Intern Med. 2006;166:1403 1409. 700. Patra J, Taylor B, Irving H, Roerecke M, Baliunas D, Mohapatra S, Rehm J. Alcohol consumption and the risk of morbidity and mortality for different stroke types: a systematic review and meta-analysis. BMC Public Health. 2010;10:258. 701. Bazzano LA, Gu D, Reynolds K, Wu X, Chen CS, Duan X, Chen J, Wildman RP, Klag MJ, He J. Alcohol consumption and risk for stroke among Chinese men. Ann Neurol. 2007;62:569 578. 702. Guiraud V, Amor MB, Mas JL, Touze E. Triggers of ischemic stroke: a systematic review. Stroke. 2010;41:2669 2677. 703. US Preventive Services Task Force. Screening and behavioral coun- seling interventions in primary care to reduce alcohol misuse. http:// www.uspreventiveservicestaskforce.org/uspstf/uspsdrin.htm. Accessed January 18, 2013. 704. US Department of Health and Human Services. Dietary guidelines for Americans -2010. http://www.health.gov/dietaryguidelines/2010.asp. Accessed March 11, 2013. 705. American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J. Diet and lifestyle rec- ommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82 96. 706. Cami J, Farre M. Drug addiction. N Engl J Med. 2003;349:975 986. 707. Brust JC. Neurological Aspects of Substance Abuse. 2nd ed. Philadelphia, PA: Butterworth-Heinemann; 2004. 708. Esse K, Fossati-Bellani M, Traylor A, Martin-Schild S. Epidemic of illicit drug use, mechanisms of action/addiction and stroke as a health hazard. Brain Behav. 2011;1:44 54. 709. Ho EL, Josephson SA, Lee HS, Smith WS. Cerebrovascular complica- tions of methamphetamine abuse. Neurocrit Care. 2009;10:295 305. 710.


Cerebrovascular complica- tions of methamphetamine abuse. Neurocrit Care. 2009;10:295 305. 710. Kaufman MJ, Levin JM, Ross MH, Lange N, Rose SL, Kukes TJ, Mendelson JH, Lukas SE, Cohen BM, Renshaw PF. Cocaine-induced cerebral vasoconstriction detected in humans with magnetic resonance angiography. JAMA. 1998;279:376 380. 711. McEvoy AW, Kitchen ND, Thomas DG. Intracerebral haemorrhage and drug abuse in young adults. Br J Neurosurg. 2000;14:449 454. 712. McGee SM, McGee DN, McGee MB. Spontaneous intracerebral hemor- rhage related to methamphetamine abuse: autopsy findings and clinical correlation. Am J Forensic Med Pathol. 2004;25:334 337. 713. Neiman J, Haapaniemi HM, Hillbom M. Neurological complica- tions of drug abuse: pathophysiological mechanisms. Eur J Neurol. 2000;7:595 606. 714. Perez JA Jr, Arsura EL, Strategos S. Methamphetamine-related stroke: four cases. J Emerg Med. 1999;17:469 471. 715. Siegel AJ, Sholar MB, Mendelson JH, Lukas SE, Kaufman MJ, Renshaw PF, McDonald JC, Lewandrowski KB, Apple FS, Stec JJ, Lipinska I, Tofler GH, Ridker PM. Cocaine-induced erythrocytosis and increase in von Willebrand factor: evidence for drug-related blood doping and pro- thrombotic effects. Arch Intern Med. 1999;159:1925 1929. 716. Saez CG, Olivares P, Pallavicini J, Panes O, Moreno N, Massardo T, Mezzano D, Pereira J. Increased number of circulating endothelial cells and plasma markers of endothelial damage in chronic cocaine users. Thromb Res. 2011;128:e18 e23. 717. Ali WM, Zubaid M, Al-Motarreb A, Singh R, Al-Shereiqi SZ, Shehab A, Rashed W, Al-Sagheer NQ, Saleh AH, Al Suwaidi J. Association of khat chewing with increased risk of stroke and death in patients presenting with acute coronary syndrome. Mayo Clin Proc. 2010;85:974 980. 718. Renard D, Taieb G, Gras-Combe G, Labauge P. Cannabis-related myo- cardial infarction and cardioembolic stroke. J Stroke Cerebrovasc Dis. 2012;21:82 83. 719. Singh NN, Pan Y, Muengtaweeponsa S, Geller TJ, Cruz-Flores S. Cannabis-related stroke: case series and review of literature.


Singh NN, Pan Y, Muengtaweeponsa S, Geller TJ, Cruz-Flores S. Cannabis-related stroke: case series and review of literature. J Stroke Cerebrovasc Dis. 2012;21:555 560. 720. Wolff V, Lauer V, Rouyer O, Sellal F, Meyer N, Raul JS, Sabourdy C, Boujan F, Jahn C, Beaujeux R, Marescaux C. Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: a prospective study in 48 consecutive young patients. Stroke. 2011;42:1778 1780. 721. Kaku DA, Lowenstein DH. Emergence of recreational drug abuse as a major risk factor for stroke in young adults. Ann Intern Med. 1990;113:821 827. 722. Kittner SJ, Stern BJ, Wozniak M, Buchholz DW, Earley CJ, Feeser BR, Johnson CJ, Macko RF, McCarter RJ, Price TR, Sherwin R, Sloan MA, Wityk RJ. Cerebral infarction in young adults: the Baltimore-Washington Cooperative Young Stroke Study. Neurology. 1998;50:890 894. 723. Levine SR, Brust JC, Futrell N, Ho KL, Blake D, Millikan CH, Brass LM, Fayad P, Schultz LR, Selwa JF, Welch KMA. Cerebrovascular com- plications of the use of the crack form of alkaloidal cocaine. N Engl J Med. 1990;323:699 704. 724. Petitti DB, Sidney S, Quesenberry C, Bernstein A. Stroke and cocaine or amphetamine use. Epidemiology. 1998;9:596 600. 725. Sloan MA, Kittner SJ, Feeser BR, Gardner J, Epstein A, Wozniak MA, Wityk RJ, Stern BJ, Price TR, Macko RF, Johnson CJ, Earley CJ, Buchholz D. Illicit drug-associated ischemic stroke in the Baltimore- Washington Young Stroke Study. Neurology. 1998;50:1688 1693. 726. Westover AN, McBride S, Haley RW. Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch Gen Psychiatry. 2007;64:495 502. 727. Martin-Schild S, Albright KC, Hallevi H, Barreto AD, Philip M, Misra V, Grotta JC, Savitz SI. Intracerebral hemorrhage in cocaine users. Stroke. 2010;41:680 684. 728.


Martin-Schild S, Albright KC, Hallevi H, Barreto AD, Philip M, Misra V, Grotta JC, Savitz SI. Intracerebral hemorrhage in cocaine users. Stroke. 2010;41:680 684. 728. Herbeck DM, HserYI, Teruya C. Empirically supported substance abuse treatment approaches: a survey of treatment providers perspectives and practices. Addict Behav. 2008;33:699 712. 729. US Preventive Services Task Force. Screening for illicit drug use. http:// www.uspreventiveservicestaskforce.org/uspstf/uspsdrug.htm. Accessed January 9, 2013. 730. Epstein LJ, Kristo D, Strollo PJ Jr, Friedman N, Malhotra A, Patil SP, Ramar K, Rogers R, Schwab RJ, Weaver EM, Weinstein MD; Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5:263 276. 731. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002;165:1217 1239. 732. Arzt M, Young T, Finn L, Skatrud JB, Bradley TD. Association of sleep- disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med. 2005;172:1447 1451. 733. Redline S, Yenokyan G, Gottlieb DJ, Shahar E, O Connor GT, Resnick HE, Diener-West M, Sanders MH, Wolf PA, Geraghty EM, Ali T, Lebowitz M, Punjabi NM. Obstructive sleep apnea-hypopnea and inci- dent stroke: the Sleep Heart Health Study. Am J Respir Crit Care Med. 2010;182:269 277. 734. Loke YK, Brown JW, Kwok CS, Niruban A, Myint PK. Association of obstructive sleep apnea with risk of serious cardiovascular events: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012;5:720 728. 735. Minoguchi K, Yokoe T, Tazaki T, Minoguchi H, Oda N, Tanaka A, Yamamoto M, Ohta S, O Donnell CP, Adachi M. Silent brain infarction and platelet activation in obstructive sleep apnea. Am J Respir Crit Care Med. 2007;175:612 617. 736.


Minoguchi K, Yokoe T, Tazaki T, Minoguchi H, Oda N, Tanaka A, Yamamoto M, Ohta S, O Donnell CP, Adachi M. Silent brain infarction and platelet activation in obstructive sleep apnea. Am J Respir Crit Care Med. 2007;175:612 617. 736. Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev. 2006:CD001106. 737. Hudgel DW, Lamerato LE, Jacobsen GR, Drake CL. Assessment of mul- tiple health risks in a single obstructive sleep apnea population. J Clin Sleep Med. 2012;8:9 18. 738. Buchner NJ, Sanner BM, Borgel J, Rump LC. Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. Am J Respir Crit Care Med. 2007;176:1274 1280. 739. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or with- out treatment with continuous positive airway pressure: an observational study. Lancet. 2005;365:1046 1053. 740. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA; on behalf of the American Heart Association Stroke Council,CouncilonCardiovascularandStrokeNursing,CouncilonClinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160 2236. 741. Martinez-Garcia MA, Campos-Rodriguez F, Soler-Cataluna JJ, Catalan- Serra P, Roman-Sanchez P, Montserrat JM. Increased incidence of non- fatal cardiovascular events in stroke patients with sleep apnoea: effect of CPAP treatment. Eur Respir J. 2012;39:906 912. Meschia et al Guidelines for the Primary Prevention of Stroke 3827 742.


Meschia et al Guidelines for the Primary Prevention of Stroke 3827 742. Ayas NT, Patel SR, Malhotra A, Schulzer M, Malhotra M, Jung D, Fleetham J, White DP. Auto-titrating versus standard continuous positive airway pressure for the treatment of obstructive sleep apnea: results of a meta-analysis. Sleep. 2004;27:249 253. 743. Berry RB, Parish JM, Hartse KM. The use of auto-titrating continuous positive airway pressure for treatment of adult obstructive sleep apnea: an American Academy of Sleep Medicine review. Sleep. 2002;25:148 173. 744. Haniffa M, Lasserson TJ, Smith I. Interventions to improve compliance with continuous positive airway pressure for obstructive sleep apnoea. Cochrane Database Syst Rev. 2004:CD003531. 745. Kakkar RK, Berry RB. Positive airway pressure treatment for obstructive sleep apnea. Chest. 2007;132:1057 1072. 746. Smith I, Lasserson TJ. Pressure modification for improving usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2009:CD003531. 747. Smith I, Nadig V, Lasserson TJ. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines for adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2009:CD007736. 748. McArdle N, Devereux G, Heidarnejad H, Engleman HM, Mackay TW, Douglas NJ. Long-term use of CPAP therapy for sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med. 1999;159(pt 1):1108 1114. 749. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the asso- ciation between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342:1378 1384. 750. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syn- drome as a risk factor for hypertension: population study. BMJ. 2000;320:479 482. 751. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, Leung RS, Bradley TD. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19:2271 2277. 752. Bazzano LA, Khan Z, Reynolds K, He J.


2001;19:2271 2277. 752. Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal con- tinuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension. 2007;50:417 423. 753. Haentjens P, Van Meerhaeghe A, Moscariello A, De Weerdt S, Poppe K, Dupont A, Velkeniers B. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syn- drome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med. 2007;167:757 764. 754. Alajmi M, Mulgrew AT, Fox J, Davidson W, Schulzer M, Mak E, Ryan CF, Fleetham J, Choi P, Ayas NT. Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials. Lung. 2007;185:67 72. 755. Colten H, Abboud F, Block G. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Washington, DC: National Academy of Sciences; 2006. 756. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540 545. 757. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1999;131:485 491. 758. Ramachandran SK, Josephs LA. A meta-analysis of clinical screening tests for obstructive sleep apnea. Anesthesiology. 2009;110:928 939. 759. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042 1050. 760. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693 2698. 761. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantita- tive assessment of plasma homocysteine as a risk factor for vascu- lar disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049 1057. 762.


A quantita- tive assessment of plasma homocysteine as a risk factor for vascu- lar disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049 1057. 762. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Medrano MJ, Candito M, Evans AE, Andria G. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997;277:1775 1781. 763. Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G, Ueland P, Rubba P, Palma-Reis R, Meleady R, Daly L, Witteman J, Graham I. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease: European COMAC Group. Circulation. 1998;97:437 443. 764. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D Agostino RB, Wilson PW, Wolf PA. Nonfasting plasma total homo- cysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med. 1999;131:352 355. 765. Das RR, Seshadri S, Beiser AS, Kelly-Hayes M, Au R, Himali JJ, Kase CS, Benjamin EJ, Polak JF, O Donnell CJ,Yoshita M, D Agostino RB Sr, DeCarli C, Wolf PA. Prevalence and correlates of silent cerebral infarcts in the Framingham Offspring Study. Stroke. 2008;39:2929 2935. 766. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: results from the Third National Health and Nutrition Examination Survey, 1988 1994. Stroke. 1998;29:2473 2477. 767. Tanne D, Haim M, Goldbourt U, Boyko V, Doolman R, AdlerY, Brunner D, Behar S, Sela BA.


Tanne D, Haim M, Goldbourt U, Boyko V, Doolman R, AdlerY, Brunner D, Behar S, Sela BA. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart dis- ease. Stroke. 2003;34:632 636. 768. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults: the Atherosclerosis Risk in Communities Study. Circulation. 1993;87:1107 1113. 769. McQuillan BM, Beilby JP, Nidorf M, Thompson PL, Hung J. Hyperhomocysteinemia but not the C677T mutation of methylenetet- rahydrofolate reductase is an independent risk determinant of carotid wall thickening: the Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Circulation. 1999;99:2383 2388. 770. Selhub J, Jacques PF, BostomAG, D Agostino RB, Wilson PW, Belanger AJ, O Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid- artery stenosis. N Engl J Med. 1995;332:286 291. 771. Kelemen LE, Anand SS, Hegele RA, Stampfer MJ, Rosner B, Willett WC, Montague PA, Lonn E, Vuksan V, Teo KK, Devanesen S, Yusuf S. Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. Atherosclerosis. 2004;176:361 370. 772. Held C, Sumner G, Sheridan P, McQueen M, Smith S, Dagenais G, Yusuf S, Lonn E. Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: base- line data from the Homocysteine and Atherosclerosis Reduction Trial (HART). Vasc Med. 2008;13:245 253. 773. Potter K, Hankey GJ, Green DJ, Eikelboom JW, Arnolda LF. Homocysteine or renal impairment: which is the real cardiovascular risk factor? Arterioscler Thromb Vasc Biol. 2008;28:1158 1164. 774. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015 2022. 775. Wald DS, Law M, Morris JK.


JAMA. 2002;288:2015 2022. 775. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202. 776. Bentley P, Peck G, Smeeth L, Whittaker J, Sharma P. Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants. PLoS One. 2010;5:e9136. 777. Al-Delaimy WK, Rexrode KM, Hu FB, Albert CM, Stampfer MJ, Willett WC, Manson JE. Folate intake and risk of stroke among women. Stroke. 2004;35:1259 1263. 778. He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC, Ascherio A. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke. 2004;35:169 174. 779. Van Guelpen B, Hultdin J, Johansson I, Stegmayr B, Hallmans G, Nilsson TK, Weinehall L, Witthoft C, Palmqvist R, Winkvist A. Folate, vitamin B12, and risk of ischemic and hemorrhagic stroke: a prospective, nested case-referent study of plasma concentrations and dietary intake. Stroke. 2005;36:1426 1431. 780. Weng LC, Yeh WT, Bai CH, Chen HJ, Chuang SY, Chang HY, Lin BF, Chen KJ, Pan WH. Is ischemic stroke risk related to folate status or other nutrients correlated with folate intake? Stroke. 2008;39:3152 3158. 781. Hodis HN, Mack WJ, Dustin L, Mahrer PR, Azen SP, Detrano R, Selhub J, Alaupovic P, Liu CR, Liu CH, Hwang J, Wilcox AG, Selzer RH; BVAIT Research Group. High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial. Stroke. 2009;40:730 736. 782. Qin X, Xu M, Zhang Y, Li J, Xu X, Wang X, Huo Y. Effect of folic acid supplementation on the progression of carotid intima-media thick- ness: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;222:307 313. 783. Potter K, Hankey GJ, Green DJ, Eikelboom J, Jamrozik K, Arnolda LF.


Potter K, Hankey GJ, Green DJ, Eikelboom J, Jamrozik K, Arnolda LF. The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a ran- domized controlled trial and meta-analysis. BMC Cardiovasc Disord. 2008;8:24. 784. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K; NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578 1588. 785. Ebbing M, Bleie O, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, Refsum H, Pedersen EK, Nygard O. Mortality and cardiovascu- lar events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300:795 804. 786. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299:2027 2036. 787. VITATOPS Study Group. B vitamins in patients with recent tran- sient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-con- trolled trial. Lancet Neurol. 2010;9:855 865. 788. Hankey GJ, Eikelboom JW, Yi Q, Lees KR, Chen C, Xavier D, Navarro JC, Ranawaka UK, Uddin W, Ricci S, Gommans J, Schmidt R; VITATOPS Trial Study Group. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol. 2012;11:512 520. 789. Yang HT, Lee M, Hong KS, Ovbiagele B, Saver JL. Efficacy of folic acid supplementation in cardiovascular disease prevention: an updated meta-analysis of randomized controlled trials. Eur J Intern Med. 2012;23:745 754. 790. Lee M, Hong KS, Chang SC, Saver JL.


2012;23:745 754. 790. Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lower- ing therapy with folic acid in stroke prevention: a meta-analysis. Stroke. 2010;41:1205 1212. 791. Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif. 2006;24:379 386. 792. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of car- diovascular events in end-stage renal disease. J Am Soc Nephrol. 2004;15:420 426. 793. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, Atkins RC, Nicholls K, Fraenkel M, Hutchison BG, Walker R, McNeil JJ. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal fail- ure: a multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006;47:1108 1116. 794. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565 575. 795. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lower- ing with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567 1577. 796. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E; Heart Outcomes Prevention Evaluation 2 Investigators. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke. 2009;40:1365 1372. 797. Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a pro- thrombotic factor: progress from bench to bedside. Curr Opin Lipidol. 2003;14:361 366. 798.


Evaluation of lipoprotein(a) as a pro- thrombotic factor: progress from bench to bedside. Curr Opin Lipidol. 2003;14:361 366. 798. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation. 2000;102:1082 1085. 799. Foody JM, Milberg JA, Pearce GL, Sprecher DL. Lipoprotein(a) associ- ated with coronary artery disease in older women: age and gender analy- sis. Atherosclerosis. 2000;153:445 451. 800. Hancock MA, Boffa MB, Marcovina SM, Nesheim ME, Koschinsky ML. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem. 2003;278:23260 23269. 801. Ariyo AA, Thach C, Tracy R; Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003;349:2108 2115. 802. Milionis HJ, Filippatos TD, Loukas T, Bairaktari ET, Tselepis AD, Elisaf MS. Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individu- als. Atherosclerosis. 2006;187:170 176. 803. Ohira T, Schreiner PJ, Morrisett JD, Chambless LE, Rosamond WD, Folsom AR. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2006;37:1407 1412. 804. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA. 1995;273:1269 1273. 805. Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, Coresh J, Mosley TH, Morrisett JD, Catellier DJ, Folsom AR, Boerwinkle E, Ballantyne CM. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012;125:241 249. 806. Klein JH, Hegele RA, Hackam DG, Koschinsky ML, Huff MW, Spence JD. Lipoprotein(a) is associated differentially with carotid ste- nosis, occlusion, and total plaque area. Arterioscler Thromb Vasc Biol. 2008;28:1851 1856. 807.


Lipoprotein(a) is associated differentially with carotid ste- nosis, occlusion, and total plaque area. Arterioscler Thromb Vasc Biol. 2008;28:1851 1856. 807. Willeit J, Kiechl S, Santer P, Oberhollenzer F, Egger G, Jarosch E, Mair A. Lipoprotein(a) and asymptomatic carotid artery disease: evidence of a prominent role in the evolution of advanced carotid plaques: the Bruneck Study. Stroke. 1995;26:1582 1587. 808. Cerrato P, Imperiale D, Fornengo P, Bruno G, Cassader M, Maffeis P, Cavallo Perin P, Pagano G, Bergamasco B. Higher lipoprotein (a) lev- els in atherothrombotic than lacunar ischemic cerebrovascular disease. Neurology. 2002;58:653 655. 809. Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta- analysis of observational studies. Stroke. 2007;38:1959 1966. 810. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D, Saleheen D, Ballantyne CM, Psaty BM, Sundstrom J, Ridker PM, Nagel D, Gillum RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RP, Assmann G, D Agostino RB Sr, Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping RW, Gomez- de-la-Camara A, Rosengren A, Sutherland SE, Gallacher J, Fowkes FG, Casiglia E, Hofman A, Salomaa V, Barrett-Connor E, Clarke R, Brunner E, Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw KT, Kauhanen J, Salonen JT, Howard WJ, Nordestgaard BG, Wood AM, Thompson SG, Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307:2499 2506. 811.


Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D, Saleheen D, Ballantyne CM, Psaty BM, Sundstrom J, Ridker PM, Nagel D, Gillum RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RP, Assmann G, D Agostino RB Sr, Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping RW, Gomez- de-la-Camara A, Rosengren A, Sutherland SE, Gallacher J, Fowkes FG, Casiglia E, Hofman A, Salomaa V, Barrett-Connor E, Clarke R, Brunner E, Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw KT, Kauhanen J, Salonen JT, Howard WJ, Nordestgaard BG, Wood AM, Thompson SG, Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307:2499 2506. 811. Kenet G, Lutkhoff LK, Albisetti M, Bernard T, Bonduel M, Brandao L, Chabrier S, ChanA, deVeber G, Fiedler B, Fullerton HJ, Goldenberg NA, Grabowski E, Gunther G, Heller C, Holzhauer S, Iorio A, Journeycake J, Junker R, Kirkham FJ, Kurnik K, Lynch JK, Male C, Manco-Johnson M, Mesters R, Monagle P, van Ommen CH, Raffini L, Rostasy K, Simioni P, Strater RD,Young G, Nowak-Gottl U. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation. 2010;121:1838 1847. 812. Goldenberg NA, Bernard TJ, Hillhouse J, Armstrong-Wells J, Galinkin J, Knapp-Clevenger R, Jacobson L, Marcovina S, Manco-Johnson MJ. Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children. Haematologica. 2013;98:802 807. 813.


Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children. Haematologica. 2013;98:802 807. 813. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844 2853. 814. Anticardiolipin antibodies are an independent risk factor for first isch- emic stroke: the Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology. 1993;43:2069 2073. 815. Dragoni F, Chiarotti F, Rosano G, Simioni P, Tormene D, Mazzucconi MG, Cafolla A, Avvisati G. Thrombophilic screening in young patients (<40 years) with idiopathic ischemic stroke: a controlled study. Thromb Res. 2011;127:85 90. 816. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, Unalp-Arida A, Vilela V, Yazici Y, Lockshin MD. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56:2382 2391. Meschia et al Guidelines for the Primary Prevention of Stroke 3829 817. Frances C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon syndrome with or without antiphospholipid antibod- ies: a comparative study in 46 patients. Medicine (Baltimore). 1999;78:209 219. 818. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117:997 1002. 819. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, Kittner SJ. Beta(2)-glycoprotein 1-dependent anticardiolipin antibod- ies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke. 2001;32:1701 1706. 820.


Beta(2)-glycoprotein 1-dependent anticardiolipin antibod- ies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke. 2001;32:1701 1706. 820. JanardhanV, Wolf PA, Kase CS, Massaro JM, D Agostino RB, Franzblau C, Wilson PW. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke. 2004;35:736 741. 821. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphos- pholipid syndrome. Blood. 2003;102:2717 2723. 822. Heinzlef O, Abuaf N, Cohen A, Amarenco P; French Study of Aortic Plaques in Stroke Group. Recurrent stroke and vascular events in elderly patients with anticardiolipin antibodies: a prospective study. J Neurol. 2001;248:373 379. 823. PengoV, RuffattiA, Legnani C, Testa S, Fierro T, Marongiu F, De Micheli V, Gresele P, Tonello M, Ghirarduzzi A, Bison E, Denas G, Banzato A, Padayattil Jose S, Iliceto S. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118:4714 4718. 824. Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S, Scarpato S, Montecucco C, Rossi S, Caramaschi P, Biasi D, Doria A, Rampudda M, Monica N, Fischetti F, Picillo U, Brucato A, Salvan E, Vittorio P, Meroni P, Tincani A; Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis. 2011;70:1083 1086. 825. Petri M. Management of thrombosis in antiphospholipid antibody syn- drome. Rheum Dis Clin North Am. 2001;27:633 642, viii. 826. Chan M, Becker RC, Shah SH, Levine SR. Coagulopathy and stroke. In: Goldstein LB, ed. A Primer on Stroke Prevention and Treatment: an Overview Based on AHA/ASA Guidelines. Oxford, UK: Wiley- Blackwell; 2009:152 169. 827.


A Primer on Stroke Prevention and Treatment: an Overview Based on AHA/ASA Guidelines. Oxford, UK: Wiley- Blackwell; 2009:152 169. 827. Pezzini A, Del Zotto E, Magoni M, Costa A, Archetti S, Grassi M, Akkawi NM, Albertini A, Assanelli D, Vignolo LA, Padovani A. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke. 2003;34:28 33. 828. Bank I, Libourel EJ, Middeldorp S, Van Pampus EC, Koopman MM, Hamulyak K, Prins MH, Van Der Meer J, Buller HR. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med. 2004;164:1932 1937. 829. Barnes C, Deveber G. Prothrombotic abnormalities in childhood isch- aemic stroke. Thromb Res. 2006;118:67 74. 830. Dalen JE. Should patients with venous thromboembolism be screened for thrombophilia? Am J Med. 2008;121:458 463. 831. Hamedani AG, Cole JW, Mitchell BD, Kittner SJ. Meta-analysis of fac- tor V Leiden and ischemic stroke in young adults: the importance of case ascertainment. Stroke. 2010;41:1599 1603. 832. Wasay M, Bakshi R, Bobustuc G, Kojan S, Sheikh Z, Dai A, Cheema Z. Cerebral venous thrombosis: analysis of a multicenter cohort from the United States. J Stroke Cerebrovasc Dis. 2008;17:49 54. 833. Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, Walker ID, Langhorne P, Brenkel I, Regan L, Greer I. Screening for throm- bophilia in high-risk situations: systematic review and cost-effective- ness analysis: the Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess. 2006;10:1 110. 834. Wells PS, Louzada ML, Taljaard M, Anderson DR, Kahn SR, Langlois NJ, Rutberg J, Kovacs MJ, Rodger MA. A pilot study to assess the feasibility of a multicenter cluster randomized trial for the manage- ment of asymptomatic persons with a thrombophilia.


A pilot study to assess the feasibility of a multicenter cluster randomized trial for the manage- ment of asymptomatic persons with a thrombophilia. J Genet Couns. 2009;18:475 482. 835. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045 2051. 836. Kamel H, Iadecola C. Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol. 2012;69:576 581. 837. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570 575. 838. Vittos O, Toana B, Vittos A, Moldoveanu E. Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker. Biomarkers. 2012;17:289 302. 839. Nambi V, Hoogeveen RC, Chambless L, Hu Y, Bang H, Coresh J, Ni H, Boerwinkle E, Mosley T, Sharrett R, Folsom AR, Ballantyne CM. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009;40:376 381. 840. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and theAmerican HeartAssociation. Circulation. 2003;107:499 511. 841. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in appar- ently healthy men. N Engl J Med. 1997;336:973 979. 842. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH.


Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731 733. 843. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D Agostino RB, Franzblau C, Wilson PW. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke. 2001;32:2575 2579. 844. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132 140. 845. Kjaergaard AD, Bojesen SE, Johansen JS, Nordestgaard BG. Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol. 2010;68:672 680. 846. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheu- matoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol. 2004;93:198 200. 847. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121(suppl 1):S9 S14. 848. Sodergren A, Stegmayr B, Lundberg V, Ohman ML, Wallberg-Jonsson S. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis. 2007;66:263 266. 849. Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovas- cular disease in patients with rheumatoid arthritis: results from a com- munity based study. Ann Rheum Dis. 2004;63:952 955. 850. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cere- brovascular disease prevalence in rheumatoid arthritis. J Rheumatol. 2003;30:36 40. 851. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 2011;7:399 408. 852.


Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 2011;7:399 408. 852. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Svendsen JH, Torp-Pedersen C, Hansen PR. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ. 2012;344:e1257. 853. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senecal JL. Traditional Framingham risk factors fail to fully account for acceler- ated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331 2337. 854. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, Kuller LH. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42:51 60. 855. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, Sammaritano L, Devereux RB, Schwartz JE, Levine DM, Salmon JE. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med. 2006;144:249 256. 856. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008;121(suppl 1):S3 S8. 857. Pearson TA. Heightened risk of cardiovascular disease in patients with rheumatoid arthritis: introduction. Am J Med. 2008;121:S1 S2. 858. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol. 2010;6:681 694. 859. Elkind MS, Ramakrishnan P, Moon YP, Boden-Albala B, Liu KM, Spitalnik SL, Rundek T, Sacco RL, Paik MC. Infectious burden and risk of stroke: the Northern Manhattan Study. Arch Neurol. 2010;67:33 38. 860. Elkind MS, Luna JM, Moon YP, Boden-Albala B, Liu KM, Spitalnik S, Rundek T, Sacco RL, Paik MC. Infectious burden and carotid plaque thickness: the Northern Manhattan Study. Stroke. 2010;41:e117-e122. 861.


Infectious burden and carotid plaque thickness: the Northern Manhattan Study. Stroke. 2010;41:e117-e122. 861. Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S, Maurer G, Mahrer P; AZACS Investigators. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet. 2003;361:809 813. 862. Zahn R, Schneider S, Frilling B, Seidl K, Tebbe U, Weber M, Gottwik M, Altmann E, Seidel F, Rox J, Hoffler U, Neuhaus KL, Senges J; Working Group of Leading Hospital Cardiologists. Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation. 2003;107:1253 1259. 863. Elkind MS, Carty CL, O Meara ES, Lumley T, Lefkowitz D, Kronmal RA, Longstreth WT Jr. Hospitalization for infection and risk of acute ischemic stroke: the Cardiovascular Health Study. Stroke. 2011;42:1851 1856. 864. Mamas MA, Fraser D, Neyses L. Cardiovascular manifestations associ- ated with influenza virus infection. Int J Cardiol. 2008;130:304 309. 865. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009;9:601 610. 866. Madjid M, Curkendall S, Blumentals WA. The influence of oseltami- vir treatment on the risk of stroke after influenza infection. Cardiology. 2009;113:98 107. 867. Grau AJ, Fischer B, Barth C, Ling P, Lichy C, Buggle F. Influenza vaccination is associated with a reduced risk of stroke. Stroke. 2005;36:1501 1506. 868. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac dis- ease and stroke among the elderly. N Engl J Med. 2003;348:1322 1332. 869. Wang CS, Wang ST, Lai CT, Lin LJ, Chou P. Impact of influenza vacci- nation on major cause-specific mortality. Vaccine. 2007;25:1196 1203. 870.


Wang CS, Wang ST, Lai CT, Lin LJ, Chou P. Impact of influenza vacci- nation on major cause-specific mortality. Vaccine. 2007;25:1196 1203. 870. Johnstone J, Loeb M, Teo KK, Gao P, Dyal L, Liu L,AvezumA, Cardona- Munoz E, Sleight P, Fagard R, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global EndPoint Trial (ONTARGET); Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Investigators. Influenza vaccination and major adverse vascular events in high-risk patients. Circulation. 2012;126:278 286. 871. Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM; American Heart Association; American College of Cardiology. Influenza vaccination as secondary preven- tion for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. Circulation. 2006;114:1549 1553. 872. De Berardis G, Lucisano G, D Ettorre A, Pellegrini F, Lepore V, Tognoni G, Nicolucci A. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307:2286 2294. 873. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple pri- mary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107:1796 1801. 874. Raju N, Sobieraj-Teague M, Hirsh J, O Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular dis- ease. Am J Med. 2011;124:621 629. 875. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collabora- tive meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849 1860. 876. US Preventive Services Task Force. Aspirin for the prevention of cardio- vascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396 404. 877.


Aspirin for the prevention of cardio- vascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396 404. 877. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases: American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388 391. 878. Hayden M, Pignone M, Phillips C, Mulrow C.Aspirin for the primary pre- vention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161 172. 879. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged anti- platelet therapy in various categories of patients: Antiplatelet Trialists Collaboration. BMJ. 1994;308:81 106. 880. Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol. 2000;57:326 332. 881. Robinson JG, Rahilly-Tierney C, Lawler E, Gaziano JM. Benefits associ- ated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older men. J Clin Lipidol. 2012;6:58 65. 882. Soejima H, Ogawa H, Morimoto T, Nakayama M, Okada S, Uemura S, Kanauchi M, Doi N, Sakuma M, Jinnouchi H, Sugiyama S, Waki M, SaitoY; JPAD Trial Investigators. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure: sub- analysis from the JPAD trial. Circ J. 2012;76:1526 1532. 883.


Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure: sub- analysis from the JPAD trial. Circ J. 2012;76:1526 1532. 883. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptom- atic peripheral arterial disease. BMJ. 2008;337:a1840. 884. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, Nicolucci A. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531. 885. Calvin AD, Aggarwal NR, Murad MH, Shi Q, Elamin MB, Geske JB, Fernandez-Balsells MM, Albuquerque FN, Lampropulos JF, Erwin PJ, Smith SA, Montori VM. Aspirin for the primary prevention of cardiovas- cular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care. 2009;32:2300 2306. 886. Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, Wang K, Zou Y, Ge J. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2010;87:211 218. 887. Stavrakis S, Stoner JA, Azar M, Wayangankar S, Thadani U. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Am J Med Sci. 2011;341:1 9. 888.


Stavrakis S, Stoner JA, Azar M, Wayangankar S, Thadani U. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Am J Med Sci. 2011;341:1 9. 888. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010;121:2694 2701. 889. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293 1304. 890. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, Ganiats TG, Gomes AS, Gornik HL, Gracia C, Gulati M, Haan CK, Judelson DR, Keenan N, Kelepouris E, Michos ED, Newby LK, Oparil S, Ouyang P, Oz MC, Petitti D, Pinn VW, Redberg RF, Scott R, Sherif K, Smith SC Jr, Sopko G, Steinhorn RH, Stone NJ, Taubert KA, Todd BA, Urbina E, Wenger NK; Expert Panel/Writing Group; American Heart Association; American Academy of Family Physicians; American College of Obstetricians and Gynecologists; American College of Cardiology Foundation; Society of Thoracic Surgeons; American Medical Women's Association; Centers for Disease Control and Prevention; Office of Research on Women's Health; Association of Black Cardiologists; American College of Physicians; World Heart Federation; National Heart, Lung, and Blood Institute; American College of Nurse Practitioners. Evidence-based guidelines for cardiovascular disease pre- vention in women: 2007 update. Circulation. 2007;115:1481 1501. Meschia et al Guidelines for the Primary Prevention of Stroke 3831 891.


Meschia et al Guidelines for the Primary Prevention of Stroke 3831 891. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for preven- tion of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841 848. 892. Uchiyama S, Demaerschalk BM, Goto S, Shinohara Y, Gotoh F, Stone WM, Money SR, Kwon SU. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis. 2009;18:482 490. 893. Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, Zoungas S, Lambers Heerspink HJ, Chalmers J, Zanchetti A. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56:956 965. 894. Centers for Disease Control and Prevention. Emergency department vis- its within the past 12 months among adults aged 18 and over, by selected characteristics: United States, selected years 1997 2011. http://www. cdc.gov/nchs/data/hus/2011/094.pdf. Accessed March 14, 2013. 895. Hsia RY, Kellermann AL, Shen YC. Factors associated with clo- sures of emergency departments in the United States. JAMA. 2011;305:1978 1985. 896. Babcock Irvin C, Wyer PC, Gerson LW. Preventive care in the emer- gency department, part II: clinical preventive services: an emergency medicine evidence-based review: Society for Academic Emergency Medicine Public Health and Education Task Force Preventive Services Work Group. Acad Emerg Med. 2000;7:1042 1054. 897. Bernstein SL, Haukoos JS. Public health, prevention, and emergency medicine: a critical juxtaposition. Acad Emerg Med. 2008;15:190 193. 898. Reeves MJ, Hogan JG, Rafferty AP. Knowledge of stroke risk factors and warning signs among Michigan adults. Neurology. 2002;59:1547 1552. 899. Marsden C, Pinell MC, Joyce SM.